MS. LISA M. HUNSICKER, MD, FACS

Plain English
This study looked at various non-cancerous problems that can arise from breast implants, finding that 20% to 30% of patients experience these benign complications. It emphasizes the need for better diagnosis and understanding of these issues, as well as the importance of careful examination of related tissues using imaging and pathology. This is significant because while breast implant-related cancers get a lot of attention, the more common benign issues also require appropriate medical response. Who this helps: This information benefits patients with breast implants and their healthcare providers.

Plain English
This study looked at how well a calculator can predict the risk of delayed kidney transplant function, known as delayed graft function (DGF), which affects about 20.4% of kidney transplants. Researchers found that the original calculator worked well for certain groups, but it didn't accurately predict risks for others, such as those receiving a simultaneous pancreas and kidney transplant or those with pump-perfused kidneys. They discovered that including information about a recipient’s heart health could make predictions more accurate. Who this helps: This helps doctors determine which kidney transplant patients might face complications, allowing for better preemptive care.

Plain English
This study looked at a specific type of inflammation (i-IFTA) in kidney transplant biopsy samples to understand its relationship with chronic rejection caused by T cells (CA TCMR). Researchers analyzed data from two groups of patients, finding that while a previous episode of acute rejection was more common in those with i-IFTA, most patients had never experienced acute rejection. Importantly, they discovered that i-IFTA scores are significant enough to impact how doctors diagnose kidney transplant rejection, indicating a need to rethink current diagnostic categories. Who this helps: This research benefits kidney transplant patients and their doctors by improving how rejection is diagnosed.

Plain English
This study looked at late kidney transplant failures, particularly focusing on a situation called "death with function," where patients die even though their transplanted kidney is still working. The researchers followed over 3,500 kidney transplant recipients for about 5 years and found that nearly 10% experienced death with function, often due to older age and existing health issues, while those who lost their grafts usually faced issues like rejection earlier on. Understanding the differences between these groups is important because it can help improve patient care and outcomes in kidney transplant programs. Who this helps: This helps kidney transplant patients and their doctors.

Plain English
This study looked at inflammation in kidney transplant biopsy samples and how it affects the survival of the transplanted organ. Researchers found that as inflammation increased—from none to severe—the chances of the graft surviving for three years decreased significantly: 81.7% survival for no inflammation, down to 48.5% for very high inflammation. This is important because it helps identify patients at greater risk of transplant failure, allowing doctors to adjust care accordingly. Who this helps: Patients who have received kidney transplants and their doctors.

Plain English
The DeKAF study looked at long-term outcomes for kidney transplant recipients who experienced new graft dysfunction after their surgery. Over an average follow-up of 6.6 years, the study found that higher inflammation in damaged areas of the kidney was linked to poorer long-term survival of the transplant. Specifically, patients with certain histologic findings had significantly different graft survival rates, with some groups showing much better outcomes than others. Who this helps: This research helps patients and doctors manage kidney transplant care more effectively by identifying high-risk groups.

Plain English
This study looked at how using small kidneys from young donors (children aged 8 years or younger and weighing less than 30 kg) can help increase the number of available kidneys for transplant. Researchers found that when comparing kidney transplants from these small pediatric donors to more traditional donor categories, the outcomes for patients were similar or even better for certain groups. Specifically, using kidneys from small donors could potentially add 159 more transplants each year, showing that these kidneys are valuable and should be used more widely. Who this helps: This benefits kidney transplant patients by increasing the number of available organs.

Plain English
This study looked at why some kidney transplants fail many years after surgery. Researchers found that while early issues like acute rejection and high creatinine levels can increase the risk of transplant failure, problems that arise later on, like dysfunction detected through biopsy, have an even greater impact on failure rates—specifically, these later issues are 13.8 times more likely to lead to transplant failure. Addressing both early and late complications quickly is crucial for improving long-term success of kidney transplants. Who this helps: Kidney transplant patients.

Plain English
This study looked at whether taking aspirin helps kidney transplant recipients lower their risks of heart disease, kidney failure, or death. Researchers matched 981 people who used aspirin with 981 people who did not, and over an average of four years, both groups experienced similar rates of heart disease events (225), deaths (200), and kidney failure (126). The findings showed that aspirin use did not reduce the risk of these health issues, indicating it may not be beneficial for this patient population. Who this helps: This helps kidney transplant recipients and their doctors in making informed decisions about aspirin use.

Plain English
This study looked at how the size of a donor's heart compared to a recipient's heart affects survival rates in heart transplants, especially when the donor and recipient are of different sexes. Researchers analyzed data from over 31,000 heart transplant pairs and found that mismatched heart sizes, particularly when the recipient's heart mass was significantly larger than the donor's, led to a 27% increase in the risk of death within the first year after the transplant. Additionally, female recipients showed worse survival rates when paired with male donors, while this wasn't observed in male recipients. Who this helps: This research benefits both patients awaiting heart transplants and doctors involved in donor-recipient matching.

Plain English
This research studied the relationship between blood pressure (BP) levels and the risk of heart disease and death in kidney transplant patients. They found that a 20-point increase in systolic BP raised the risk of heart disease by 32% and the risk of death by 13%. Additionally, when diastolic BP dropped below 70 mmHg, a 10-point decrease also raised both heart disease and mortality risks by about 31%. Who this helps: This information benefits kidney transplant patients and their doctors in managing blood pressure to reduce health risks.

Plain English
This study looked at how the size of donor lungs compared to the recipients' lungs affects survival after lung transplants. It found that for patients receiving both lungs (bilateral lung transplantation), a better match in lung size led to a 7% lower risk of death in the first year after surgery. In contrast, similar size matching did not show a significant survival benefit for patients receiving just one lung (single lung transplantation). This research highlights the importance of matching lung sizes to improve outcomes, especially for those getting both lungs. Who this helps: This helps patients undergoing lung transplants, particularly those receiving both lungs.

Plain English
This study examined how kidney function impacts the risk of heart disease and death in people who have received kidney transplants. Researchers analyzed data from nearly 4,000 transplant recipients and found that for every 5-point decrease in kidney function (measured by eGFR) below 45, the risk of developing heart disease or dying decreased by 15%. This is important because it shows that maintaining better kidney function can help reduce serious health risks for these patients. Who this helps: This benefits kidney transplant recipients and their healthcare providers, guiding treatment and management.

Plain English
This study looked at whether taking high doses of certain vitamins could lower the levels of homocysteine, an amino acid linked to heart disease, in kidney transplant patients. Researchers followed over 4,100 kidney transplant recipients for an average of four years and found that while the high-dose vitamins did lower homocysteine levels, they did not reduce heart disease events or death rates. This is important because it shows that lowering homocysteine alone may not be enough to improve heart health in these patients. Who this helps: Kidney transplant patients at risk for heart disease.

Plain English
This study looked at the effects of frequent nocturnal hemodialysis, where patients receive treatment six times a week overnight, compared to traditional hemodialysis that occurs three times a week. It included 87 patients, and while those on nocturnal hemodialysis received more treatments and spent more time on dialysis, the study did not show a clear benefit in terms of reducing death rates or heart problems. However, patients on nocturnal hemodialysis performed better in managing phosphate levels and high blood pressure. Who this helps: This research benefits patients with kidney failure who are considering different hemodialysis options.

Plain English
This study looked at kidney transplant patients who experienced problems with their transplants years after the surgery. Researchers analyzed 265 biopsies and found that by grouping the results, they could identify six distinct subgroups with different survival rates for the kidney transplants after the biopsies were performed. Specifically, the chances of keeping the transplant alive after the biopsy varied significantly among these groups (with a significance level of p = 0.002), even though common issues like chronic rejection were prevalent across all clusters. Who this helps: This research benefits doctors treating kidney transplant patients by providing clearer subgroups to guide diagnosis and treatment decisions.

Plain English
This study looked at kidney transplant patients to better understand what causes problems with the transplant over time. In a group of 440 patients, 48% had chronic allograft nephropathy (CAN), 30% showed damage from medications, and 23% experienced acute rejection. After one year, 17.7% of these patients lost their transplant, and by two years, that number rose to 29.8%. This research is important because it aims to identify the main issues affecting kidney transplants, which can lead to better treatments in the future. Who this helps: Patients who have received kidney transplants.

Plain English
This study looked at 173 kidney transplant patients who experienced new kidney problems about 7 years after their surgeries. The researchers found that 57% of these patients had signs of antibody-related injury, and those with this injury (particularly those with a substance called C4d) were at a much higher risk of their transplant failing in the following two years. Specifically, the patients showing C4d staining had significantly worse outcomes compared to those without it. Who this helps: This information is valuable for doctors managing kidney transplant patients, as they can better identify those at risk for late graft failure.

Plain English
This study looked at inflammation in kidney transplant biopsies, particularly in areas where the tissue was damaged and not functioning well. Among 337 kidney transplant recipients with new issues, researchers found that inflammation in these damaged areas was a strong predictor of transplant failure, with a risk more than doubled for those with inflammation compared to those without. This matters because understanding these inflammation signals can help doctors better predict and manage the survival of kidney transplants. Who this helps: This research benefits patients with kidney transplants by improving monitoring and treatment strategies.

Plain English
This study looked at kidney transplant patients to gather information about their health before starting a trial that tests the effects of high doses of folic acid and other vitamins on lowering homocysteine levels, which could help reduce cardiovascular problems. Out of 4,110 participants, 38.9% had diabetes, and 19.5% had a history of heart disease. On average, their homocysteine levels were 17.1 micromol/L, indicating that many were at risk for heart-related issues. Who this helps: This research benefits kidney transplant recipients at high risk for heart disease.

Plain English
This study looked at how kidney transplant patients in the US and Canada are prescribed heart-protecting medications after their surgery. Among nearly 1,000 patients, 87% were given blood pressure medications soon after their transplant, but only 24% were using heart-protective drugs like ACE inhibitors six months later—especially concerning for those with diabetes or heart disease. This variability in treatment shows a lack of consistent care, which is important because these medications can help prevent heart problems in transplant patients. Who this helps: Patients who have received a kidney transplant, especially those with diabetes or heart disease.

Plain English
This study looked at the number of brain-dead individuals who could potentially donate their organs in the U.S. over three years and found about 18,524 potential donors. It reported that only 42% of these potential donors actually became donors due to families not consenting to the donations, particularly in larger hospitals where more potential donors are found. This research is important because improving the process of obtaining consent in big hospitals could lead to more organs being available for transplant, helping to reduce waiting lists and save lives. Who this helps: Patients in need of organ transplants.

Plain English
This study looked at the effects of bone marrow transfusions on kidney transplants from deceased donors. Researchers tested three different treatment methods involving immunosuppressive drugs along with bone marrow infusions. They found that while the initial survival rates of the transplanted kidneys were better for those who received bone marrow (38 patients) compared to those who did not (35 patients), both groups had similar outcomes after five years, and there were no serious complications from the transfusions. Who this helps: This benefits kidney transplant patients, especially those who are Black, as they showed lower rejection rates.

Plain English
This study looked at how cutting back on protein in the diet and controlling blood pressure affects the progression of kidney disease in 840 patients. Researchers found that while a low-protein diet seemed to help slow the decline in kidney function after about four months, it didn't result in a significant difference in overall kidney health compared to normal protein intake after three years. For those with severe kidney issues, a very-low-protein diet did not show clear benefits over a standard low-protein diet. Who this helps: Patients with chronic kidney disease.